Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 When better still might not be good enough.

Literature DB >> 30214854

When better still might not be good enough.

Waldemar Debinski^1,2.

Abstract

Entities: CellLine Chemical Disease Gene Species

Year: 2017 PMID： 30214854 PMCID： PMC6132272 DOI： 10.21037/tcr.2017.09.40

Source DB: PubMed Journal: Transl Cancer Res ISSN： 2218-676X Impact factor: 1.241

× No keyword cloud information.

26 in total

1. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors: Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal: J Clin Oncol Date: 2017-07-17 Impact factor: 44.544

2. EphA2 as a novel molecular marker and target in glioblastoma multiforme.

Authors: Jill Wykosky; Denise M Gibo; Constance Stanton; Waldemar Debinski
Journal: Mol Cancer Res Date: 2005-10 Impact factor: 5.852

Review 3. An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link.

Authors: W Debinski
Journal: Crit Rev Oncog Date: 1998

4. Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245

Review 5. Interleukin-15 biology and its therapeutic implications in cancer.

Authors: Jason C Steel; Thomas A Waldmann; John C Morris
Journal: Trends Pharmacol Sci Date: 2011-10-25 Impact factor: 14.819

6. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Authors: Bryan W Day; Brett W Stringer; Fares Al-Ejeh; Michael J Ting; John Wilson; Kathleen S Ensbey; Paul R Jamieson; Zara C Bruce; Yi Chieh Lim; Carolin Offenhäuser; Sara Charmsaz; Leanne T Cooper; Jennifer K Ellacott; Angus Harding; Lucie Leveque; Po Inglis; Suzanne Allan; David G Walker; Martin Lackmann; Geoffrey Osborne; Kum Kum Khanna; Brent A Reynolds; Jason D Lickliter; Andrew W Boyd
Journal: Cancer Cell Date: 2013-02-11 Impact factor: 31.743

7. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Authors: Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie
Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245

8. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors.

Authors: J P Thompson; W Debinski
Journal: J Biol Chem Date: 1999-10-15 Impact factor: 5.157

9. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

Authors: Fumiyoshi Okano; Walter J Storkus; William H Chambers; Ian F Pollack; Hideho Okada
Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531